Pyelonephritis Market Insights, Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 12/31/2019 --Pyelonephritis Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Pyelonephritis Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report

1. One in 830 people in the United Kingdom experience pyelonephritis every year and females are six times more likely to experience the infection than males.
2. Approximately 20–35% of females experience an episode of acute pyelonephritis in their lifetime.

Key benefits of the report

1. Pyelonephritis market report covers a descriptive overview and comprehensive insight of the Pyelonephritis epidemiology and Pyelonephritis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Pyelonephritis market report provides insights on the current and emerging therapies.
3. Pyelonephritis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Pyelonephritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pyelonephritis market.

Request for sample pages

"The incidence of acute pyelonephritis is highest in healthy women 15 to 29 years of age, followed by infants and older persons"

Antimicrobial agents are useful for pyelonephritis treatment. Antimicrobial selection and route of administration are guided by local microbial resistance patterns and the ability of the patient to take and retain oral agents. Children who are suspected of having pyelonephritis are started empirically on antibiotics effective against the usual pathogens for their clinical condition. Oral drugs such as fluoroquinolones (ciprofloxacin (Cipro), and moxifloxacin), trimethoprim-sulfamethoxazole (TMP-SMX/Bactrim and others), amoxicillin, ampicillin, sulfonamides, and nitrofurantoin are useful in the management of pyelonephritis (Sherif Labatia, n.d.). Parenteral doses of the ceftriaxone, fluoroquinolones, gentamicin, and aztreonam are also used. Ampicillin and gentamicin are effective against the aerobic gram-negative bacilli and enterococci respectively. Cephalosporins, TMP-SMX, and penicillin/beta-lactamase inhibitor combination can be used as the alternative medicines for these regimens. The intramuscular dose of ceftriaxone or gentamicin can be administered to children who are presumed to have pyelonephritis and not require hospitalization, followed by oral antibiotics. Oral antibiotics can be used as empirical therapy in patients well enough to take oral medications. TMP- SMX is considered as a standard first-line oral agent in many cases and may be more effective than beta- lactams at treating urinary tract infections(UTIs). However, it is not effective against the TMP-SMX resistant E coli. In this case cephalosporins, penicillin/beta-lactamase inhibitor combinations and ciprofloxacin (for a child older than 12 months) are considered as an alternative.

In patients with confirmed pyelonephritis, antimicrobial susceptibility testing results should guide therapy. The use of amoxicillin or TMP-SMX is suggested for these patients. The available evidence from some randomized trials comparing pyelonephritis treatment regimens in children suggests that 10 to 14 days of antimicrobial therapy is sufficient for uncomplicated pyelonephritis. After completion of 10 to 14 days of antibiotics for their initial UTI, children ages 2 months to 2 years should be continued on prophylactic antibiotics until imaging studies are completed and vesicoureteral reflux is excluded.

The launch of the emerging therapies is expected to significantly impact Pyelonephritis treatment scenario in the upcoming years:-
Drugs covered
1. CONTEPO
2. WCK 4282
3. SPR994
4. Cefepime-Enmetazobactam/AAI101
And many others

The key players in Pyelonephritis market are:
1. Wockhardt
2. Spero Therapeutics
3. Allecra Therapeutics
4. VenatoRx Pharmaceuticals
5. Nabriva Therapeutics
And many others

Table of contents
1. Report Introduction
2. Pyelonephritis Market Overview at a Glance
3. Pyelonephritis Disease Background and Overview
4. Pyelonephritis Epidemiology and Patient Population
5. Pyelonephritis Country-Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Pyelonephritis Treatments & Medical Practices
7. Pyelonephritis Marketed Products
7.1. CIPRO: Bayer HealthCare Pharmaceuticals
8. Pyelonephritis Emerging Therapies
8.1. Key Cross Competition
8.2. WCK 4282: Wockhardt
8.3. SPR994: Spero Therapeutics
8.4. Cefepime-Enmetazobactam/AAI101: Allecra
8.5. CONTEPO (ZTI-01); Nabriva Therapeutics
9. Pyelonephritis Market Size
10. 7MM Pyelonephritis Country-Wise Market Analysis
10.1.United States Market Size
10.2.Germany Market Size
10.3. France Market Size
10.4.Italy Market Size
10.5. Spain Market Size
10.6.United Kingdom Market Size
10.7.Japan Market Size
11. Market Drivers
12. Market Barriers
13. Appendix
14. Pyelonephritis Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.